These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28399128)

  • 1. Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells.
    Zeng Y; Liu B; Rubio MT; Wang X; Ojcius DM; Tang R; Durrbach A; Ru Z; Zhou Y; Lone YC
    PLoS One; 2017; 12(4):e0173754. PubMed ID: 28399128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.
    Zeng Y; Gao T; Zhao G; Jiang Y; Yang Y; Yu H; Kou Z; Lone Y; Sun S; Zhou Y
    Hum Vaccin Immunother; 2016 Mar; 12(3):829-36. PubMed ID: 26479036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.
    Pajot A; Michel ML; Fazilleau N; Pancré V; Auriault C; Ojcius DM; Lemonnier FA; Lone YC
    Eur J Immunol; 2004 Nov; 34(11):3060-9. PubMed ID: 15468058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells.
    Büchner SM; Sliva K; Bonig H; Völker I; Waibler Z; Kirberg J; Schnierle BS
    Clin Exp Immunol; 2013 Aug; 173(2):355-64. PubMed ID: 23607364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein.
    Ru Z; Xiao W; Pajot A; Kou Z; Sun S; Maillere B; Zhao G; Ojcius DM; Lone YC; Zhou Y
    PLoS One; 2012; 7(3):e32247. PubMed ID: 22403638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
    Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
    Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
    Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
    Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.
    Ehx G; Somja J; Warnatz HJ; Ritacco C; Hannon M; Delens L; Fransolet G; Delvenne P; Muller J; Beguin Y; Lehrach H; Belle L; Humblet-Baron S; Baron F
    Front Immunol; 2018; 9():1943. PubMed ID: 30214443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects.
    Pajot A; Michel ML; Mancini-Bourgine M; Ungeheuer MN; Ojcius DM; Deng Q; Lemonnier FA; Lone YC
    Microbes Infect; 2006 Oct; 8(12-13):2783-90. PubMed ID: 17045504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
    Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
    Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses.
    Yaguchi T; Kobayashi A; Inozume T; Morii K; Nagumo H; Nishio H; Iwata T; Ka Y; Katano I; Ito R; Ito M; Kawakami Y
    Cell Mol Immunol; 2018 Nov; 15(11):953-962. PubMed ID: 29151581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
    Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
    Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines.
    Zeng B; Moi D; Tolley L; Molotkov N; Frazer IH; Perry C; Dolcetti R; Mazzieri R; Cruz JLG
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
    Marsac D; Puaux AL; Rivière Y; Michel ML
    Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HLA-DR1-restricted T cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules.
    Pajot A; Pancré V; Fazilleau N; Michel ML; Angyalosi G; Ojcius DM; Auriault C; Lemonnier FA; Lone YC
    Int Immunol; 2004 Sep; 16(9):1275-82. PubMed ID: 15249541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological responses against hepatitis B virus in human peripheral blood mononuclear cell-engrafted mice.
    Aono S; Tatsumi T; Yoshioka T; Tawara S; Nishio A; Onishi Y; Fukutomi K; Nakabori T; Kodama T; Shigekawa M; Hikita H; Sakamori R; Takahashi T; Suemizu H; Takehara T
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1457-1464. PubMed ID: 30033102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
    Hung CF; Calizo R; Tsai YC; He L; Wu TC
    Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.